ArticlePharmacological reports : PR2026
Signs of antidepressant-like effects of temozolomide as measured in the forced-swim test in adult rats.
Article in Pharmacological reports : PR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundTemozolomide is the gold standard chemotherapeutic agent for glioblastoma multiforme. Yet its pharmacological use has been linked to the emergence of depressive- and/or anxiety-like behaviors, probably through the inhibition of hippocampal neurogenesis. Since prior studies reporting these negative effects were based on prolonged treatment paradigms (from 2 weeks to up to 6 months), and given the lack of studies including females, our approach aimed at further characterizing the behavioral effects induced by temozolomide (25 mg/kg, 1 or 2 cycles, 5 days/cycle) in a adult rats of both sexes.
methodsRats were scored across time through specific behavioral tests that capture diverse manifestations of affective-like responses (forced-swim, open field, novelty-suppressed feeding, sucrose preference) or cognitive performance (Barnes maze). At the neurochemical level, we ascertained the effects of 2 cycles of temozolomide on an early stage of hippocampal neurogenesis (neural progenitors, NeuroD) and other potential neuroplasticity targets (mature BDNF, FADD).
resultsTemozolomide induced signs of antidepressant-like responses as measured in the forced-swim test in a treatment-duration manner. It also decreased NeuroD and hippocampal FADD, a neuroplastic marker previously associated with the acute and repeated actions of most antidepressants. These results suggested that other mechanisms of action might be associated with temozolomide's behavioral effects besides hippocampal neurogenesis, such as the correlative one described through the neuroplastic molecule FADD.
conclusionsIn conjunction with the prior data, our results suggested cycle- and/or length-dependent treatment effects in terms of temozolomide's antidepressant- vs. depressant-like profile, while proposing a novel biomarker related to treatment response.
Indexed as
Identifiers
42678583What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.